Lisata Therapeutics (Nasdaq:LSTA) - Aandelenkoers, Nieuws & Analyse

LSTA Overzicht aandelen

Lisata Therapeutics, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en op de markt brengen van innovatieve therapieën voor de behandeling van solide tumoren en andere ziekten. Meer informatie

LSTA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 3.2% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( $24M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Lisata Therapeutics, Inc. Concurrenten

Enlivex Therapeutics

NasdaqCM:ENLV

US$18.0m

Bolt Biotherapeutics

NasdaqGS:BOLT

US$21.7m

Equillium

NasdaqCM:EQ

US$25.5m

CytoMed Therapeutics

NasdaqCM:GDTC

US$25.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Lisata Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$2.88
52 Week Hoogtepunt	US$3.83
52 Week Laag	US$2.05
Bèta	1.22
11 maand verandering	-0.81%
3 maanden verandering	-4.00%
1 Jaar Verandering	18.28%
33 jaar verandering	-80.41%
5 jaar verandering	-93.14%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30

Rendement voor aandeelhouders

	LSTA	US Biotechs	US Markt
7D	1.1%	2.4%	2.2%
1Y	18.3%	16.2%	31.7%

Rendement versus industrie: LSTA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 16.2 % opleverde.

Rendement versus markt: LSTA presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is LSTA's price volatile compared to industry and market?
LSTA volatility
LSTA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: LSTA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van LSTA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1980	25	Dave Mazzo	www.lisata.com

Lisata Therapeutics, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken, ontwikkelen en commercialiseren van innovatieve therapieën voor de behandeling van vaste tumoren en andere ziekten. Tot haar productkandidaten behoren LSTA1, dat zich in Fase 2a en 2b van klinische studies bevindt voor de behandeling van vaste tumoren, waaronder metastatisch pancreas ductaal adenocarcinoom (mPDAC), in combinatie met een reeks antikankerbehandelingen; XOWNA dat zich in Fase IIa van klinische studie bevindt voor de behandeling van coronaire microvasculaire disfunctie; en CD34+ celtherapie voor de behandeling van chronische nieraandoeningen. Lisata Therapeutics, Inc. werd opgericht in 1980 en het hoofdkantoor is gevestigd in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Lisata Therapeutics zich tot de beurswaarde?
LSTA fundamentele statistieken
Marktkapitalisatie	US$23.66m
Inkomsten(TTM)	-US$20.74m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.2x

Koers/Winstverhouding

Is LSTA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LSTA resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$20.74m
Inkomsten	-US$20.74m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.49
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde LSTA op de lange termijn?

Bekijk historische prestaties en vergelijking

LSTA Overzicht aandelen

Risicoanalyse

Lisata Therapeutics, Inc. Concurrenten

NasdaqCM:ENLV

US$18.0m

NasdaqGS:BOLT

US$21.7m

NasdaqCM:EQ

US$25.5m

NasdaqCM:GDTC

US$25.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Recent updates

Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Price target decreased to US$8.00

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Price target decreased to US$9.00

Consensus forecasts updated

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Price target decreased to US$8.67

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Analysts update estimates

Price target lowered to US$8.50

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

New 90-day high: US$2.89

Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius suspends CLBS119 COVID-19 study

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Price target raised to US$12.75

Caladrius Biosciences, Inc. Announces Executive Changes

New 90-day low: US$1.47